Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 6/20 | 0.95 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.72 |
| ▸ | TACR1 known ✓ | P25103 | 1/20 | 0.44 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.44 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.44 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.44 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.44 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.44 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.42 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.42 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.42 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.42 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.41 |
| ▸ | AKT2 | P31751 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL738518 | 0.98 | OPRM1 (1.00) | OPRM1HTR2AAKT2MEN1CYP2C9 | |
| SCHEMBL7885473 | 0.89 | OPRM1 (0.83) | OPRM1HTR2AAKT2MEN1CYP2C9 | |
| Hydrochloric Acid SCHEMBL1765122 | 0.88 | OPRM1 (0.74) | OPRM1HTR2AAKT2MEN1CYP2C9 | |
| Hydrochloric Acid SCHEMBL6197352 | 0.88 | OPRM1 (0.74) | OPRM1HTR2AAKT2MEN1CYP2C9 | |
| Hydrochloric Acid SCHEMBL1764619 | 0.88 | OPRM1 (0.74) | OPRM1HTR2AAKT2MEN1CYP2C9 | |
| Hydrochloric Acid SCHEMBL3695425 | 0.86 | HTR2A (0.96) | OPRM1HTR2AAKT2MEN1CYP2C9 | |
| Acetic Acid SCHEMBL8333150 | 0.86 | OPRM1 (0.77) | OPRM1HTR2AAKT2MEN1CYP2C9 | |
| SCHEMBL1257446 | 0.86 | OPRM1 (0.77) | OPRM1HTR2AAKT2MEN1CYP2C9 | |
| SCHEMBL1977652 | 0.86 | OPRM1 (0.77) | OPRM1HTR2AAKT2MEN1CYP2C9 | |
| SCHEMBL2313435 | 0.84 | HTR2A (1.00) | OPRM1HTR2AAKT2MEN1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937676-B1 | BIOCOMPATIBLE FLUORESCENT IMAGING AGENTS | VISEN MEDICAL INC (US) | 2016-11-30 | — | — | EP | disclosed |
| CN-102753538-B | Sultam derivatives | HOFFMANN LA ROCHE | 2015-04-08 | — | — | CN | disclosed |
| EP-2504324-B1 | SULTAM DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-02-25 | — | — | EP | disclosed |
| US-8314250-B2 | Sultam derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-20 | — | — | US | disclosed |
| CN-102753538-A | Sultam derivatives | HOFFMANN LA ROCHE | 2012-10-24 | — | — | CN | disclosed |
| EP-2504324-A1 | SULTAM DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011064141-A1 | SULTAM DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-03 | — | — | WO | disclosed |
| US-7951806-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20110124686-A1 | SULTAM DERIVATIVES | ANDERSON KEVIN W | 2011-05-26 | — | — | US | disclosed |
| US-7947256-B2 | Biocompatible fluorescent imaging agents | VISEN MEDICAL, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-4994461-A | Vasodilators; treating cardiovascular disorders | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1991-02-19 | — | — | US | disclosed |
| EP-0401256-A1 | OPTICALLY PURE DEXNIGULDIPINE AND ITS DERIVATIVES FOR TREATING TUMOROUS DISEASES. | BYK GULDEN LOMBERG CHEM FAB (DE) | 1990-12-12 | — | — | EP | disclosed |
| US-4975440-A | Hypotensive or cardiotonic agents or diuretics | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1990-12-04 | — | — | US | disclosed |
| EP-0343193-A1 | 1,4-DIHYDROPYRIDINE ENANTIOMERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1989-11-29 | — | — | EP | disclosed |
| WO-1989007443-A1 | OPTICALLY PURE R-(-)-NIGULDIPINE AND ITS DERIVATIVES FOR TREATING TUMOROUS DISEASES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1989-08-24 | — | — | WO | disclosed |
| EP-0296316-A1 | 1,4-Dihydropyridine enantiomers | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1988-12-28 | — | — | EP | disclosed |
| WO-1988007531-A1 | NEW OPTICALLY ACTIVE COMPOUNDS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1988-10-06 | — | — | WO | disclosed |
| WO-1988007525-A1 | 1,4-DIHYDROPYRIDINE ENANTIOMERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1988-10-06 | — | — | WO | disclosed |
| US-4022786-A | PHARMACEUTICALS, CNS STIMULANT | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1977-05-10 | — | — | US | disclosed |
| US-4016280-A | 4,4-Diarylpiperidine compositions and use | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124686-A1 | SULTAM DERIVATIVES | SULT1A1, SULT2A1, SULT1E1 | OPRM1 376/4885HTR2A 2103/4885TACR1 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.